Friday, February 12, 2016

'Heroes of Chemistry' award to hepatitis C team from Merck

A team from Merck that led the creation of a new treatment for the hepatitis C virus will be among the honorees at the American Chemical Society's "Heroes of Chemistry" dinner in Philadelphia on Sunday.

'Heroes of Chemistry' award to hepatitis C team from Merck


The American Chemical Society will hold its 224th national meeting in Philadelphia starting Sunday and the five-day gathering kickoffs with a dinner at the Four Seasons Hotel to honor "Heroes of Chemistry."

The 2012 honorees include a group of scientists who developed the hepatitis C drug Victrelis, while working at Schering Plough and then Merck after it acquired Schering Plough in 2009.

Merck researchers in North Wales and Kenilworth, N.J., were among the hundreds who worked on the drug, which doctors hoped would be an improvement on a two-drug cocktail that had been used for more than a decade.

The five scientists honored include F. George Njoroge (one of the patent holders who has since moved to Eli Lilly and Company), Srikanth Venkatraman, Stephane Bogen, Frank Bennett and Ashok Arasappan.

Companies nominate a scientist, or teams of them, for the award. According to the ACS website, the award "has recognized chemical scientists whose work in various fields of chemistry and chemical engineering has led to the successful innovation and development of commercial products based on chemistry. The Heroes of Chemistry program highlights the vital role of industrial chemical scientists and their companies in improving human welfare through successful commercial innovations and products. It presents an ideal opportunity to enhance the public image of the chemical and allied industries."

The World Health Organization said in 2011 that the hepatitis C virus affects 130 million to 170 million people worldwide - about four times the number with HIV/AIDS - and kills about 350,000 people a year because of damage to the liver.

In its second-quarter earnings report, Merck said it sold $126 million of Victrelis. (Boceprevir is the chemical name.) It is approved in 43 countries and has launched in 23 of those markets, Merck said.

Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter